Prognostic models incorporating immune features—such as a ceRNA network involving MASTL, or populations including CD4+ memory T cells, monocytes, and neutrophils—show utility in predicting clinical outcomes in gastric cancer (69). The gene discussed is CD4; the disease is gastric cancer.